CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy

Table 1 Comparison between pre- and intra-operative data between patients with and without non-alcoholic fatty liver disease after pancreatoduodenectomy

	Non-NAFLD	NAFLD	P value1
	(n = 52)	(n = 30)
BMI (kg/m2)	21.7 ± 3.3	21.4 ± 2.6	0.622
Age (yr)	63.6 ± 10.9	63.4 ± 11.9	0.940
Pancreatic head cancer (yes)	31%	53%	< 0.0012
Sex (male)	69%	43%	0.0352
Diameter of MPD (mm)	3.9 ± 3.2	5.6 ± 3.2	0.025
Total cholesterol (mg/dL)3	188.2 ± 53.3	202.0 ± 39.9	0.238
Triglycerides (mg/dL)3	119.8 ± 69.2	139.9 ± 74.8	0.363
Total protein (g/dL)3	8.0 ± 0.9	8.3 ± 0.5	0.322
Albumin (g/dL)3	4.0 ± 0.4	4.0 ± 0.5	0.761
Cholinesterase (U/L)3	230.6 ± 88.2	244.5 ± 104.9	0.531
Insulin (μU/mL)3	5.5 ± 2.3	7.7 ± 3.5	0.500
HOMA-IR3	1.6 ± 1.0	3.2 ± 3.4	0.324
HbA1c (%)3	5.5 ± 0.8	6.2 ± 1.8	0.060
ALT3	65.6 ± 0.8	79.9 ± 107.3	0.506
Operation (PPPD)	15%	10%	0.7382
Operation time (min)	400.9 ± 49.0	394.6 ± 37.8	0.544
Intraoperative blood loss (mL)	425.2 ± 171.9	419.3 ± 155.6	0.878
Patients with nerve plexus dissection	15%	93%	< 0.0012
Pancreatic resection line (SMA)	19%	37%	0.0812

¹P values calculated using the χ² test;

²P values calculated using Fisher’s exact test;

³Values represent mean ± SD unless otherwise indicated. NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index; MPD: Main pancreatic duct; HOMA-IR: Homeostasis model assessment for insulin resistance; HbA1c: Hemoglobin A1c; ALT: Alanine aminotransferase; PPPD: Pylorus preserving pancreaticoduodenectomy; SMA: Superior mesenteric artery.